User Fee Program Has Not Changed “Risk Threshold,” CDER’s Galson Says
This article was originally published in The Tan Sheet
Executive Summary
FDA sees no evidence of a change in its risk threshold as a result of the user fee program, Center for Drug Evaluation & Research Acting Director Steven Galson said during an April 15 meeting of FDA's Science Board